Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 EP673 | DOI: 10.1530/endoabs.90.EP673

ECE2023 Eposter Presentations Pituitary and Neuroendocrinology (234 abstracts)

Hyponatraemia post endoscopic pituitary surgery: A tertiary centre experience of a large cohort

Alicja Knysak 1 , Nijaguna Mathad 1 , Jonathan Hempenstall 1 , Jana Bujanova 2 & Ma’en Al-Mrayat 2


1University Hospital Southampton, Wessex Neurological Centre, Southampton, UK; 2University Hospital Southampton, Diabetes and Endocrinology, Southampton, UK


Post-pituitary surgery hyponatraemia (HN, sodium <135 mmol/l) is relatively common and may result in prolonged hospitalisation. Herein we report a retrospective analysis of our experience in a tertiary institute. We conducted a retrospective case note review of 318 patients (M 54%, F 46%, mean age 58 years) 65.7% non-functioning adenoma (NFA), 10% somatotropinoma, 5% prolactinoma, 11% corticotropinoma (half were clinically silent), 8% craniopharyngioma, and 0.3% FSHoma, who underwent endoscopic transphenoidal surgery between 2019 and 2022. Of those 28 patients (19F, 9M) developed post-surgery HN (9% of total), of whom 54% were above 70 years of age, 61% with NFA and 18% with corticotropinoma. Of those with HN, 39% developed it within 1–3 days of surgery and 61% between 5 and 10 days. The majority had no evidence of prior hormone deficiency (61%), while 36% had pre-operative HN. The severity of HN as follows: mild (130–135 mmol/l) 7%, moderate (125–129 mmol/l) 61% and severe (<125 mmol/l)32%. The majority (68%) were on a pre-operative medication that can cause low sodium including: diuretics, ACE inhibitors, angiotensin receptor antagonists, proton pump inhibitors and antidepressants. Only 9 of 318 total patients undergoing pituitary surgery (2.9%) required readmission due to HN and that is 32% of hyponatraemia cases, most of whom had pre-operative HN or on medication that can caused it, with 54% having HN resolved within 3 days, and 32% within 5–7 days. The management of post-operative HN consisted of 43% fluid restriction (FR) alone, 32% FR and oral sodium tablets, 18% FR and medication review, 15% 1.8% sodium infusion and remaining had a combination of interventions. Our HN incidence is lower than some of the published large cohorts, mostly mild-moderate and not requiring hospital readmission. We have identified several predictive risk factors for development of post-surgery HN: pre-operative sodium, medications, advanced age and female gender, and thus proactive risk mitigation may reduce its occurrence and readmission rate.

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.